Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
G6PD	2539	GLYCOLIC ACID	CHEMBL252557		DrugBank	17139284, 17016423
G6PD	2539	CHEMBL1161862	CHEMBL1161862		DrugBank	17139284, 17016423
G6PD	2539	CHEMBL445472	CHEMBL445472		DrugBank
G6PD	2539	QUININE SULFATE	CHEMBL2359966		FDA
G6PD	2539	NIMESULIDE	CHEMBL56367		NCI	12839301
G6PD	2539	CHLORPROGUANIL	CHEMBL1213553		PharmGKB
G6PD	2539	ARTESUNATE	CHEMBL361497		PharmGKB
G6PD	2539	GLYBURIDE	CHEMBL472		PharmGKB, FDA
G6PD	2539	SULFISOXAZOLE	CHEMBL453		FDA
G6PD	2539	SODIUM SULFATE	CHEMBL233406		FDA
G6PD	2539	ASCORBATE	CHEMBL196		NCI, FDA	9101560
G6PD	2539	CHLOROQUINE	CHEMBL76		FDA
G6PD	2539	ERYTHROMYCIN	CHEMBL532		FDA
G6PD	2539	RASBURICASE	CHEMBL1201594		PharmGKB, FDA
G6PD	2539	SULFAMETHOXAZOLE	CHEMBL443		FDA
G6PD	2539	PREDNISOLONE	CHEMBL131		NCI	16324786
G6PD	2539	TRIAPINE	CHEMBL231616		PharmGKB
G6PD	2539	CARMUSTINE	CHEMBL513		PharmGKB
G6PD	2539	BUSULFAN	CHEMBL820		NCI	2635153
G6PD	2539	METOCLOPRAMIDE	CHEMBL86		FDA
G6PD	2539	GLIMEPIRIDE	CHEMBL1481		FDA
G6PD	2539	PRILOCAINE	CHEMBL1194		FDA
G6PD	2539	SODIUM CHLORIDE	CHEMBL1200574		FDA
G6PD	2539	SUCCIMER	CHEMBL1201073		FDA
G6PD	2539	SULFASALAZINE	CHEMBL421		FDA
G6PD	2539	PYRIMETHAMINE	CHEMBL36		PharmGKB
G6PD	2539	NALIDIXIC ACID	CHEMBL5		FDA
G6PD	2539	CHLORPROPAMIDE	CHEMBL498		FDA
G6PD	2539	PEGLOTICASE	CHEMBL1237025		FDA
G6PD	2539	POTASSIUM CHLORIDE	CHEMBL1200731		FDA
G6PD	2539	NITROFURANTOIN	CHEMBL572		FDA
G6PD	2539	PRIMAQUINE	CHEMBL506		PharmGKB, FDA
G6PD	2539	TRAMETINIB	CHEMBL2103875		FDA
G6PD	2539	DIAZEPAM	CHEMBL12		NCI	12020046
G6PD	2539	OMEPRAZOLE	CHEMBL1503		NCI	16570509
G6PD	2539	PROPRANOLOL	CHEMBL27		NCI	10395986
G6PD	2539	ZINC CHLORIDE	CHEMBL1200679		NCI	15596258
G6PD	2539	METHYLENE BLUE	CHEMBL191083		PharmGKB, FDA
G6PD	2539	SULFADOXINE	CHEMBL1539		PharmGKB
G6PD	2539	DABRAFENIB	CHEMBL2028663		CGI
G6PD	2539	LIDOCAINE	CHEMBL79		FDA
G6PD	2539	GLIPIZIDE	CHEMBL1073		FDA
G6PD	2539	MAFENIDE	CHEMBL419		FDA
G6PD	2539	SODIUM NITRITE	CHEMBL93268		FDA
G6PD	2539	SODIUM ASCORBATE	CHEMBL591665		FDA
G6PD	2539	TRIMETHOPRIM	CHEMBL22		FDA
G6PD	2539	TRIAMCINOLONE	CHEMBL1451		NCI	1197440
G6PD	2539	ETHYL NITROSOUREA	CHEMBL167667		NCI	9330624
G6PD	2539	CO-TRIMOXAZOLE	CHEMBL58061		NCI	46571
G6PD	2539	PENICILLIN G POTASSIUM	CHEMBL1223		NCI	12530481

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
G6PD	G6PD deficiency		daunorubicin	efficacy	no	No significant association between G6PD deficient genotypes and the number of patients who achieve minimal residual disease (MRD) >1% following daunorubicin treatment.	G6PD deficiency is not associated with response to daunorubicin in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.	30848065	1450935426
G6PD	G6PD A- 202A_376G	A-202A_376G	daunorubicin	metabolism/PK	yes	In vitro assays with A- G6PD deficient erythrocytes vs non-deficient erythrocytes. Please note; G6PD variant was determined by enzyme activity/ phenotype (not by genotyping).	G6PD A-202A_376G is associated with decreased metabolism of daunorubicin.	8648264	1183685450
G6PD	rs1050828	T	artemisinin and derivatives	efficacy	no	G6PD deficient (those with genotype TT, TC, or T in males) compared to non-deficient (genotype CC or C in males). No difference in efficacy of parasite clearance was observed. Patients were treated with artemether-lumefantrine or artesunate and mefloquine.	Allele T is not associated with response to artemisinin and derivatives in people with Malaria, Falciparum as compared to allele C.	22940027	1183705675
G6PD	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham	daunorubicin	metabolism/PK	not stated	In vitro assays with Mediterranean G6PD deficient erythrocytes vs non-deficient erythrocytes. Please note; G6PD variant was determined by enzyme activity/ phenotype (not by genotyping).	G6PD Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham is associated with decreased metabolism of daunorubicin.	8648264	1184516039